Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Flixotide 50 micrograms Evohaler.
Flixotide 125 micrograms Evohaler.
Flixotide 250 micrograms Evohaler.
| Pharmaceutical Form |
|---|
|
Pressurised inhalation, suspension. Flixotide Evohaler does not contain any chlorofluorocarbons (CFCs). |
Flixotide 50 micrograms Evohaler, Flixotide 125 micrograms Evohaler and Flixotide 250 micrograms Evohaler are pressurised inhalation, suspensions, delivering either 50, 125 or 250 micrograms of fluticasone propionate per actuation, respectively.
| Active Ingredient | Description | |
|---|---|---|
| Fluticasone |
Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. |
| List of Excipients |
|---|
|
HFA 134a |
An inhaler comprising an aluminium alloy can sealed with a metering valve, actuator and dust cap. Each canister contains 120 metered actuations of either 50, 125 or 250 micrograms of fluticasone propionate. (60 metered actuation hospital packs are available in the 125 or 250 microgram products).
Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Flixotide 50 micrograms Evohaler: PL 10949/0324
Flixotide 125 micrograms Evohaler: PL 10949/0265
Flixotide 250 micrograms Evohaler: PL 10949/0266
Flixotide Evohaler 50 micrograms: 27 June 2000
Flixotide Evohaler 125/250 micrograms: 14 March 2000
| Drug | Countries | |
|---|---|---|
| FLIXOTIDE | Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
